The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling
Open accessAbstract
Inflammation in arterial walls leads to coronary artery disease (CAD). Because specialized proresolving lipid mediators (SPMs; lipoxins, resolvins, and protectins) stimulate resolution of inflammation in animal models, we tested whether n‐3 fatty acids impact SPM profiles in patients with CAD and promote clot remodeling. Six patients with stable CAD were randomly assigned to either treatment with daily 3.36 g Lovaza for 1 yr or without. Targeted lipid mediator‐metabololipidomics showed that both groups had absence of resolvin D1 (RvD1), RvD2, RvD3, RvD5 and resolvin E1—all of which are present in healthy patients. Those not taking Lovaza had an absence of aspirin‐triggered resolvin D3 (AT‐RvD3) and aspirin‐triggered lipoxin B 4 (AT‐LXB 4 ). Lovaza treatment restored AT‐RvD3 and AT‐LXB 4 and gave levels of RvD6 and aspirin‐triggered protectin D1 (AT‐PD1) twice as high (resolvin E2 ~5 fold) as well as lower prostaglandins. Principal component analysis indicated positive relationships for patients with CAD who were receiving Lovaza with increased AT‐RvD3, RvD6, AT‐PD1, and AT‐LXB4.SPMs identified in Lovaza‐treated patients with CAD enhanced ~50% at 1 nM macrophage uptake of blood clots. These results indicate that patients with CAD have lower levels and/or absence of specific SPMs that were restored with Lovaza; these SPMs promote macrophage phagocytosis of blood clots. Together, they suggest that low vascular SPMs may enable progression of chronic vascular inflammation predisposing to coronary atherosclerosis and to thrombosis.—Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., Welty, F. K. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 30, 2792‐2801 (2016). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“aspirin-triggered, pro-resolving omega-3 fatty acid derivatives can be detected in patients with diabetes and coronary artery disease who were treated with a mixture of DHA and EPA concomitantly with aspirin and statins126.”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Self-citationn−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525
(1999) · PubMed · Cited by 2,062
Psychogios, N., Hau, D., Peng, J., Guo, A. C., Mandal, R., Bouatra, S., Sinelnikov, I. V., Krishnamurthy, R., Eisner, R., Gautam, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016957 · Cited by 1,779
Robbins and Cotran Pathologic Basis of Disease
Hoda, S. A., & Hoda, R. S. (2005) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000155072.86944.7d · Cited by 1,566
Lipid mediator class switching during acute inflammation: signals in resolution
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001) · Nature Immunology · doi:10.1038/89759 · Cited by 1,453
Self-citationDistribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease
Haeggström, J. Z., & Funk, C. D. (2011) · Chemical Reviews · doi:10.1021/cr200246d · Cited by 875
The Effect of Polyphenols in Olive Oil on Heart Disease Risk Factors: A Randomized Trial
Covas, M.-I., Nyyssönen, K., Poulsen, H. E., Kaikkonen, J., Zunft, H.-J. F., Kiesewetter, H., Gaddi, A., de la Torre, R., Mursu, J., Bäumler, H., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-5-200609050-00006 · Cited by 758
Dalli, J., & Serhan, C. N. (2012) · Blood · doi:10.1182/blood-2012-04-423525 · Cited by 572
Self-citationn–3 Fatty Acids in Cardiovascular Disease
Caterina, R. D. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1008153 · Cited by 572
Inflammation and its Resolution as Determinants of Acute Coronary Syndromes
Libby, P., Tabas, I. A., Fredman, G., & Fisher, E. A. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302699 · Cited by 531
Colas, R. A., Shinohara, M., Dalli, J., Chiang, N., & Serhan, C. N. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00024.2014 · Cited by 437
Self-citationMerched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N., & Chan, L. (2008) · The FASEB Journal · doi:10.1096/fj.08-112201 · Cited by 414
Self-citationDefective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway
Karp, C. L., Flick, L. M., Park, K. W., Softic, S., Greer, T. M., Keledjian, R., Yang, R., Uddin, J., Guggino, W. B., Atabani, S. F., et al. (2004) · Nature Immunology · doi:10.1038/ni1056 · Cited by 344
Scoditti, E., Calabriso, N., Massaro, M., Pellegrino, M., Storelli, C., Martines, G., Caterina, R. D., & Carluccio, M. A. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.05.003 · Cited by 323
Safety and Efficacy of Omacor in Severe Hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679700400511 · Cited by 306
Mozaffarian, D., Lemaitre, R. N., King, I. B., Song, X., Huang, H., Sacks, F. M., Rimm, E. B., Wang, M., & Siscovick, D. S. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00003 · Cited by 283
Mas, E., Croft, K. D., Zahra, P., Barden, A., & Mori, T. A. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.190199 · Cited by 270
Chiang, N., Bermudez, E. A., Ridker, P. M., Hurwitz, S., & Serhan, C. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405445101 · Cited by 266
Self-citationSchwingshackl, L., Christoph, M., & Hoffmann, G. (2015) · Nutrients · doi:10.3390/nu7095356 · Cited by 252
Safety and efficacy of Omacor in severe hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199710000-00011 · Cited by 252
Diminished Lipoxin Biosynthesis in Severe Asthma
Levy, B. D., Bonnans, C., Silverman, E. S., Palmer, L. J., Marigowda, G., & Israel, E. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1413oc · Cited by 250
Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution
Kasuga, K., Yang, R., Porter, T. F., Agrawal, N., Petasis, N. A., Irimia, D., Toner, M., & Serhan, C. N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8677 · Cited by 241
Self-citationKain, V., Ingle, K. A., Colas, R. A., Dalli, J., Prabhu, S. D., Serhan, C. N., Joshi, M. D., & Halade, G. V. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.04.003 · Cited by 237
Self-citationDona, M., Fredman, G., Schwab, J. M., Chiang, N., Arita, M., Goodarzi, A., Cheng, G., von Andrian, U. H., & Serhan, C. N. (2008) · Blood · doi:10.1182/blood-2007-11-122598 · Cited by 228
Self-citationHo, K. J., Spite, M., Owens, C. D., Lancero, H., Kroemer, A. H. K., Pande, R., Creager, M. A., Serhan, C. N., & Conte, M. S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091082 · Cited by 204
Self-citationHasturk, H., Abdallah, R., Kantarci, A., Nguyen, D., Giordano, N., Hamilton, J., & Van Dyke, T. E. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305324 · Cited by 199
Omega-3 Polyunsaturated Fatty Acids and the Treatment of Rheumatoid Arthritis: A Meta-analysis
Lee, Y. H., Bae, S., & Song, G. G. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.06.011 · Cited by 197
Otto, M. C. D. O., Wu, J. H. Y., Baylín, A., Vaidya, D. M., Rich, S. S., Tsai, M. Y., Jacobs, D. R., & Mozaffarian, D. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000506 · Cited by 179
Birnbaum, Y., Ye, Y., Lin, Y., Freeberg, S. Y., Nishi, S. P. E., Martinez, J. D., Huang, M.-H., Uretsky, B. F., & Perez-Polo, J. R. (2006) · Circulation · doi:10.1161/circulationaha.106.629907 · Cited by 172
Impaired Phagocytosis in Localized Aggressive Periodontitis: Rescue by Resolvin E1
Fredman, G., Oh, S. F., Ayilavarapu, S., Hastürk, H., Serhan, C. N., & Dyke, T. E. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024422 · Cited by 160
Self-citationRole of Basic Science in the Development of New Medicines: Examples from the Eicosanoid Field
Samuelsson, B. O. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.x112.351437 · Cited by 157
Casula, M., Soranna, D., Catapano, A. L., & Corrao, G. (2013) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(13)70005-9 · Cited by 152
Miyahara, T., Runge, S. J., Chatterjee, A., Chen, M., Mottola, G., Fitzgerald, J. M., Serhan, C. N., & Conte, M. S. (2013) · The FASEB Journal · doi:10.1096/fj.12-225615 · Cited by 134
Self-citationResolvin E1 Metabolome in Local Inactivation during Inflammation-Resolution
Hong, S., Porter, T. F., Lu, Y., Oh, S. F., Pillai, P. S., & Serhan, C. N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3512 · Cited by 107
Self-citationAkagi, D., Chen, M., Toy, R., Chatterjee, A., & Conte, M. S. (2015) · The FASEB Journal · doi:10.1096/fj.14-265363 · Cited by 106
Cleland, L. G., Caughey, G. E., James, M. J., & Proudman, S. (2006) · PubMed · Cited by 104
Chatterjee, A., Sharma, A., Chen, M., Toy, R., Mottola, G., & Conte, M. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113480 · Cited by 95
Barden, A. E., Mas, E., Croft, K. D., Phillips, M. R., & Mori, T. A. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m045583 · Cited by 89
Amano, T., Matsubara, T., Uetani, T., Kato, M., Kato, B., Yoshida, T., Harada, K., Kumagai, S., Kunimura, A., Shinbo, Y., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.05.030 · Cited by 83
Yacoubian, S., & Serhan, C. N. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0616 · Cited by 81
Self-citationn-3 Fatty acid supplementation and proresolving mediators of inflammation
Barden, A. E., Mas, E., & Mori, T. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000262 · Cited by 77
Determination of ω-6 and ω-3 PUFA metabolites in human urine samples using UPLC/MS/MS
Sasaki, A., Fukuda, H., Shiida, N., Tanaka, N. K., Furugen, A., Ogura, J., Shuto, S., Mano, N., & Yamaguchi, H. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8412-5 · Cited by 58
James, M. J., Proudman, S., & Cleland, L. G. (2003) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(03)00064-4 · Cited by 54
Assimes, T. L., Knowles, J. W., Priest, J. R., Basu, A., Borchert, A., Volcik, K. A., Grove, M. L., Tabor, H. K., Southwick, A. M., Tabibiazar, R., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.003 · Cited by 49
Leeb, B. F., Sautner, J., Andel, I., & Rintelen, B. (2006) · Lipids · doi:10.1007/11745-006-5066-x · Cited by 41
Wittwer, J., Bayer, M., Mosandl, A., Muntwyler, J., & Hersberger, M. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.103 · Cited by 39
Cited by
Sorted by citations
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341
Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators
Serhan, C. N., & Levy, B. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97943 · Cited by 1,344
Self-citationSerhan, C. N. (2017) · The FASEB Journal · doi:10.1096/fj.201601222r · Cited by 566
Self-citationFredman, G., Hellmann, J., Proto, J. D., Kuriakose, G., Colas, R. A., Dorweiler, B., Connolly, E. S., Solomon, R., Jones, D. M., Heyer, E. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12859 · Cited by 411
Self-citationChiang, N., & Serhan, C. N. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.03.005 · Cited by 338
Self-citation
Metadata
- Authors
- Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., & Welty, F. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Welty, Francine K.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2016-04-27
- Volume
- 30
- Issue
- 8
- Pages
- 2792-2801
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC4970606
- OpenAlex
- W2344216384
- Cited by
- 143
- References
- 51
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 11 · 2023: 17 · 2022: 23 · 2021: 10 · 2020: 15 · 2019: 19 · 2018: 13 · 2017: 17 · 2016: 5
- FWCI
- 18.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The FASEB Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (P01GM095467, RO1GM03865, P50HL083813)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, omega-3 fatty acids, lipoxin B4, protectin D1, vascular inflammation, thrombosis, atherosclerosis
- MeSH terms
- Aged, Aspirin, Coronary Disease, Docosahexaenoic Acids, Drug Combinations, Female, Gene Expression Regulation, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Eicosapentaenoic Acid, Biomarkers, Fatty Acids, Omega-3, Lipoxins, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
